Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLI1 | Q01543 | 5/20 | 1.00 |
| ▸ | EWSR1 | Q01844 | 5/20 | 1.00 |
| ▸ | ERG | P11308 | 1/20 | 1.00 |
| ▸ | ETV1 | P50549 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 5/20 | 0.64 |
| ▸ | MMP9 | P14780 | 5/20 | 0.64 |
| ▸ | MMP8 | P22894 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CBX7 | O95931 | 1/20 | 0.47 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19829782 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL29399443 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL3486735 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL29810794 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17679820 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17669251 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17679823 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL15337311 | 0.89 | FLI1 (0.80) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL19419557 | 0.88 | FLI1 (0.78) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL15337268 | 0.88 | FLI1 (0.78) | FLI1EWSR1ERGETV1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101435-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-27 | — | — | US | disclosed |
| US-20240052354-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-02-15 | — | — | US | disclosed |
| US-11530413-B2 | Compositions and methods to treat cancer | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| US-11530413-B2 | Compositions and methods to treat cancer | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| EP-4085919-A2 | COMPOSITIONS AND METHODS TO TREAT CANCER | Novartis AG (CH) | 2022-11-09 | — | — | EP | disclosed |
| US-20210155932-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210155932-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2021-05-27 | — | — | US | disclosed |
| US-20180028495-A1 | USES OF INDOLINONE COMPOUNDS | GEORGETOWN UNIVERSITY | 2018-02-01 | — | — | US | disclosed |
| US-20180028495-A1 | USES OF INDOLINONE COMPOUNDS | GEORGETOWN UNIVERSITY | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240052354-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | TP53, BRCA1, NTPCR | FLI1 1409/4885EWSR1 1763/4885ERG 2315/4885 |
| US-20180028495-A1 | USES OF INDOLINONE COMPOUNDS | MCL1, BCL3, BCL9 | FLI1 8/4885EWSR1 823/4885ERG 311/4885 |
| US-20210155932-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | TP53, BRCA1, NTPCR | FLI1 1409/4885EWSR1 1763/4885ERG 2315/4885 |
| US-11530413-B2 | Compositions and methods to treat cancer | TP53, BRCA1, NTPCR | FLI1 1409/4885EWSR1 1763/4885ERG 2315/4885 |
| US-20250101435-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | TP53, BRCA1, NTPCR | FLI1 1409/4885EWSR1 1763/4885ERG 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.